These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 22447885)

  • 1. Long-term outcome of patients with JIA treated with etanercept, results of the biologic register JuMBO.
    Minden K; Niewerth M; Zink A; Seipelt E; Foeldvari I; Girschick H; Ganser G; Horneff G
    Rheumatology (Oxford); 2012 Aug; 51(8):1407-15. PubMed ID: 22447885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register.
    Prince FH; Twilt M; ten Cate R; van Rossum MA; Armbrust W; Hoppenreijs EP; van Santen-Hoeufft M; Koopman-Keemink Y; Wulffraat NM; van Suijlekom-Smit LW
    Ann Rheum Dis; 2009 May; 68(5):635-41. PubMed ID: 18413443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of inflammatory bowel disease in patients with juvenile idiopathic arthritis treated with etanercept.
    van Dijken TD; Vastert SJ; Gerloni VM; Pontikaki I; Linnemann K; Girschick H; Armbrust W; Minden K; Prince FH; Kokke FT; Nieuwenhuis EE; Horneff G; Wulffraat NM
    J Rheumatol; 2011 Jul; 38(7):1441-6. PubMed ID: 21459936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumour necrosis factor-blocking agents in persistent oligoarticular juvenile idiopathic arthritis: results from the Dutch Arthritis and Biologicals in Children Register.
    Anink J; Otten MH; Prince FH; Hoppenreijs EP; Wulffraat NM; Swart JF; ten Cate R; van Rossum MA; van den Berg JM; Dolman KM; Koopman-Keemink Y; Armbrust W; Kamphuis S; van Pelt PA; Gorter SL; van Suijlekom-Smit LW
    Rheumatology (Oxford); 2013 Apr; 52(4):712-7. PubMed ID: 23267169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type.
    Quartier P; Taupin P; Bourdeaut F; Lemelle I; Pillet P; Bost M; Sibilia J; Koné-Paut I; Gandon-Laloum S; LeBideau M; Bader-Meunier B; Mouy R; Debré M; Landais P; Prieur AM
    Arthritis Rheum; 2003 Apr; 48(4):1093-101. PubMed ID: 12687553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry.
    Horneff G; De Bock F; Foeldvari I; Girschick HJ; Michels H; Moebius D; Schmeling H;
    Ann Rheum Dis; 2009 Apr; 68(4):519-25. PubMed ID: 18413440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of etanercept in a cohort of patients with juvenile idiopathic arthritis under 4 years of age.
    Bracaglia C; Buonuomo PS; Tozzi AE; Pardeo M; Nicolai R; Campana A; Insalaco A; Cortis E; DE Benedetti F
    J Rheumatol; 2012 Jun; 39(6):1287-90. PubMed ID: 22589254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients.
    Gerloni V; Pontikaki I; Gattinara M; Fantini F
    Ann Rheum Dis; 2008 Aug; 67(8):1145-52. PubMed ID: 17981916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experiences with tumour necrosis factor-{alpha} inhibitors in patients with juvenile idiopathic arthritis: Hungarian data from the National Institute of Rheumatology and Physiotherapy Registry.
    Sevcic K; Orban I; Brodszky V; Bazso A; Balogh Z; Poor G; Kiss E
    Rheumatology (Oxford); 2011 Jul; 50(7):1337-40. PubMed ID: 21372001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complete control of disease activity and remission induced by treatment with etanercept in juvenile idiopathic arthritis.
    Papsdorf V; Horneff G
    Rheumatology (Oxford); 2011 Jan; 50(1):214-21. PubMed ID: 21148155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The German etanercept registry for treatment of juvenile idiopathic arthritis.
    Horneff G; Schmeling H; Biedermann T; Foeldvari I; Ganser G; Girschick HJ; Hospach T; Huppertz HI; Keitzer R; Küster RM; Michels H; Moebius D; Rogalski B; Thon A;
    Ann Rheum Dis; 2004 Dec; 63(12):1638-44. PubMed ID: 15115709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Biologics register JuMBO. Long-term safety of biologic therapy of juvenile idiopathic arthritis].
    Minden K; Klotsche J; Niewerth M; Horneff G; Zink A
    Z Rheumatol; 2013 May; 72(4):339-46. PubMed ID: 23456365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improvement in health-related quality of life for children with juvenile idiopathic arthritis after start of treatment with etanercept.
    Klotsche J; Minden K; Thon A; Ganser G; Urban A; Horneff G
    Arthritis Care Res (Hoboken); 2014 Feb; 66(2):253-62. PubMed ID: 23983081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment choices of paediatric rheumatologists for juvenile idiopathic arthritis: etanercept or adalimumab?
    Anink J; Otten MH; Gorter SL; Prince FH; van Rossum MA; van den Berg JM; van Pelt PA; Kamphuis S; Brinkman DM; Swen WA; Swart JF; Wulffraat NM; Dolman KM; Koopman-Keemink Y; Hoppenreijs EP; Armbrust W; ten Cate R; van Suijlekom-Smit LW
    Rheumatology (Oxford); 2013 Sep; 52(9):1674-9. PubMed ID: 23740187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ongoing disease activity and changing categories in a long-term nordic cohort study of juvenile idiopathic arthritis.
    Nordal E; Zak M; Aalto K; Berntson L; Fasth A; Herlin T; Lahdenne P; Nielsen S; Straume B; Rygg M;
    Arthritis Rheum; 2011 Sep; 63(9):2809-18. PubMed ID: 21560116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors associated with achievement of inactive disease in children with juvenile idiopathic arthritis treated with etanercept.
    Solari N; Palmisani E; Consolaro A; Pistorio A; Viola S; Buoncompagni A; Gattorno M; Picco P; Ruperto N; Malattia C; Martini A; Ravelli A
    J Rheumatol; 2013 Feb; 40(2):192-200. PubMed ID: 23204218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis.
    Lovell DJ; Reiff A; Jones OY; Schneider R; Nocton J; Stein LD; Gedalia A; Ilowite NT; Wallace CA; Whitmore JB; White B; Giannini EH;
    Arthritis Rheum; 2006 Jun; 54(6):1987-94. PubMed ID: 16732547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors associated with treatment response to etanercept in juvenile idiopathic arthritis.
    Otten MH; Prince FH; Armbrust W; ten Cate R; Hoppenreijs EP; Twilt M; Koopman-Keemink Y; Gorter SL; Dolman KM; Swart JF; van den Berg JM; Wulffraat NM; van Rossum MA; van Suijlekom-Smit LW
    JAMA; 2011 Dec; 306(21):2340-7. PubMed ID: 22056397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of response criteria to evaluate therapeutic response in patients with juvenile idiopathic arthritis treated with methotrexate and/or anti-tumor necrosis factor alpha agents.
    Lurati A; Pontikaki I; Teruzzi B; Desiati F; Gerloni V; Gattinara M; Cimaz R; Fantini F
    Arthritis Rheum; 2006 May; 54(5):1602-7. PubMed ID: 16646003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and safety of a second and third biological agent after failing etanercept in juvenile idiopathic arthritis: results from the Dutch National ABC Register.
    Otten MH; Prince FH; Anink J; Ten Cate R; Hoppenreijs EP; Armbrust W; Koopman-Keemink Y; van Pelt PA; Kamphuis S; Gorter SL; Dolman KM; Swart JF; van den Berg JM; Wulffraat NM; van Rossum MA; van Suijlekom-Smit LW
    Ann Rheum Dis; 2013 May; 72(5):721-7. PubMed ID: 22730374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.